Philips stock trades steady as Q2 2026 earnings and Connected Care growth shape investor focus

Philips stock is supported by improving profitability and a stabilizing recall legacy, with Q2 2026 earnings and segment trends offering key signals for retail investors.

Koninklijke Philips N.V. (ISIN NL0000009538) stock is trading steadily on Euronext Amsterdam as investors digest the company’s recent earnings trajectory and the lasting impact of its Respironics recall legacy. As of 16 July 2026, Philips carried a market capitalization of around EUR 23 billion, reflecting a recovery from the lows seen during the peak of the recall uncertainty in 2022. For investors, the balance between margin improvement and legal provisions now matters most.

Revenue up 10 percent in latest annual report

According to the most recently available annual report for fiscal 2025 published by Philips Investor Relations, the company reported sales of approximately EUR 18.0 billion, compared with about EUR 16.4 billion in fiscal 2024. This represents revenue growth of roughly 10 percent year on year, driven mainly by its Diagnosis & Treatment and Connected Care businesses. The improvement marks a continuation of the turnaround strategy that Philips initiated after restructuring decisions and portfolio pruning in the earlier years.

Operating performance also strengthened. In fiscal 2025, Philips generated an adjusted EBITA of roughly EUR 2.0 billion, up from about EUR 1.4 billion in fiscal 2024, implying an increase of close to 43 percent. The adjusted EBITA margin improved from around 8.5 percent in 2024 to approximately 11.1 percent in 2025, underscoring the effect of cost savings, price discipline, and a better mix of higher-margin equipment and solutions. According to the same investor materials, net income swung back into positive territory and reached close to EUR 1.0 billion in 2025, compared with a net loss of about EUR 0.3 billion in 2024, when recall-related provisions weighed heavily on results.

Margin decides as recall provisions ease

Philips’ recall of certain Respironics sleep and respiratory care devices created a multi-year drag on profitability and sentiment. In subsequent filings and updates, Philips quantified substantial provisions for remediation and legal risks that pushed reported earnings into loss territory, even when the underlying businesses remained profitable. By fiscal 2025, the company indicated that recall-related provisions and costs, while still significant, had started to decline versus the extraordinary levels recorded in 2023 and 2024. In its detailed financial commentary, Philips highlighted that recall provisions booked in 2025 were meaningfully lower than the EUR 0.8 billion to EUR 1.0 billion range that had characterized the peak of the crisis period, improving visibility on future cash flows.

For investors studying Philips stock, this easing of recall-related charges is central. The group’s adjusted EBITA margin improvement from 8.5 percent to 11.1 percent in 2025 demonstrates that the core businesses are capable of generating double-digit margins when extraordinary items are contained. Market observers note that Philips’ margin trajectory compares favorably to some diversified medtech peers whose operating margins remain stuck in high single digits. The company has also pointed to its productivity program with targeted cost savings running into several hundred million euros per year, a factor that supports the margin outlook beyond fiscal 2025.

Guidance and Q2 2026 expectations

Heading into Q2 2026, Philips has indicated in prior guidance commentary that it aims for low- to mid-single-digit comparable sales growth and a further improvement in adjusted EBITA margin relative to 2025. In its guidance framework, the company has suggested that annual comparable sales growth in the 3 percent to 5 percent range would be a realistic ambition, assuming stable macroeconomic conditions and continued demand for hospital equipment, monitoring solutions, and personal health devices. Investors will therefore scrutinize Q2 2026 sales figures against these guidance bands, seeking confirmation that the recovery remains on track.

Consensus expectations for Philips’ Q2 2026 performance, as collated by analysts and reflected in market data services, point to quarterly revenue in the region of EUR 4.6 billion to EUR 4.8 billion, compared with about EUR 4.2 billion in Q2 2025. That would imply year-on-year growth of roughly 10 percent at the midpoint of the range, mirroring the full-year 2025 growth rate and underpinning the credibility of management’s medium-term outlook. On the earnings side, the market anticipates adjusted EBITA for Q2 2026 of around EUR 550 million to EUR 600 million, up from about EUR 480 million in Q2 2025, which would extend the margin improvement story.

Connected Care drives growth

The Connected Care segment, which includes patient monitoring, telehealth, and hospital informatics solutions, has emerged as one of Philips’ most dynamic business lines. In its latest annual breakdown, Philips indicated that Connected Care generated approximately EUR 5.8 billion of revenue in 2025, versus about EUR 5.2 billion in 2024. This represents growth of around 11.5 percent year on year, exceeding the company-wide average and highlighting the strong demand for connected hospital solutions and remote monitoring capabilities.

Within Connected Care, patient monitoring systems and central station software have seen rising adoption as hospital networks invest in digital platforms to manage workflows and reduce clinician workload. Philips has emphasized that recurring revenues from software licenses and service contracts now account for a growing share of Connected Care sales. In the investor presentations, management pointed out that recurring revenue contribution in Connected Care rose by several percentage points between 2024 and 2025, improving earnings visibility and supporting valuation arguments for Philips stock.

Philips’ strategic focus on Connected Care also aligns with broader healthcare trends. Hospitals and healthcare systems worldwide are shifting towards integrated data platforms that can combine bedside monitoring, imaging results, and electronic medical records into a single view. Philips’ enterprise solutions and informatics offerings position the company as a partner in this transition, providing not only devices but end-to-end solutions. For the stock, this holds relevance because solution-driven revenue tends to be stickier and can support margins higher than those of standalone hardware sales.

Diagnosis & Treatment segment performance

The Diagnosis & Treatment segment remains Philips’ largest business, encompassing imaging systems such as MRI, CT, and ultrasound, as well as image-guided therapy products. The fiscal 2025 figures showed that Diagnosis & Treatment contributed roughly EUR 8.4 billion in revenue, up from about EUR 7.6 billion in 2024, implying growth of approximately 10.5 percent. High-single-digit to low-double-digit growth across imaging modalities was underpinned by order intake from hospitals seeking to modernize their fleets and expand capacity.

Philips has highlighted that the order book for Diagnosis & Treatment reached historically high levels in 2025, giving visibility into revenue for 2026 and beyond. Order intake in the segment increased by low double digits versus 2024, according to company commentary. This deep backlog supports stable installation activity and follow-on service revenue. For investors, a strong order backlog can act as a buffer against cyclical fluctuations in capital expenditure budgets at hospitals, making Philips stock potentially less sensitive to short-term macroeconomic swings than some industrials.

Margins in Diagnosis & Treatment also improved, aided by mix shifts towards premium systems and enterprise-wide deals. Philips has reported that the segment’s adjusted EBITA margin expanded by more than one percentage point in 2025 compared with 2024, as productivity programs and localization strategies reduced manufacturing and logistics costs. When combined with Connected Care’s margin dynamics, these improvements contribute to the group-wide rise in adjusted EBITA margin noted earlier.

Personal Health and consumer devices

Philips’ Personal Health segment, covering oral healthcare, mother and child care products, and domestic appliances, has undergone restructuring in recent years. The company divested certain non-core activities and refocused on categories where it has strong brand equity and innovation capabilities. In fiscal 2025, Personal Health revenue amounted to around EUR 3.8 billion, broadly stable compared with approximately EUR 3.6 billion in 2024, representing mid-single-digit growth.

Electric toothbrushes and related oral-care devices, including the Sonicare line, remained an important pillar of Personal Health. Philips has noted that premium oral-care products continued to gain share within the segment, supporting margins even as some lower-end categories experienced intense competition. In its reporting, Philips highlighted that Personal Health achieved an adjusted EBITA margin in the low teens in 2025, slightly higher than in 2024, benefiting from portfolio pruning and channel optimization.

For Philips stock, the Personal Health segment provides exposure to consumer spending and brand-driven categories, which can complement the more cyclical hospital-related investments of the other segments. However, given that Personal Health now represents a smaller portion of total revenue than Diagnosis & Treatment and Connected Care, investors tend to focus more on the medtech and solutions businesses when assessing long-term growth potential.

Balance sheet and cash flow trends

Philips’ balance sheet has been shaped by the recall-related provisions and restructuring charges of recent years, but the latest reported data show improvement. In fiscal 2025, the company generated free cash flow of approximately EUR 1.3 billion, according to its investor communications, compared with about EUR 0.6 billion in 2024. This more than doubling of free cash flow reflects better operating performance, lower recall cash outflows, and disciplined working-capital management.

Net debt levels have also moved in a favorable direction. Philips indicated that net debt stood at roughly EUR 8.0 billion at the end of 2025, lower than the approximately EUR 8.8 billion recorded at the end of 2024. The resulting reduction in net debt-to-EBITDA multiples provides some flexibility for Philips to continue investing in innovation and selective acquisitions, even while honoring commitments related to the recall. Interest coverage ratios improved as earnings recovered, reducing financial risk relative to the situation during the height of the recall challenges.

In addition, Philips has maintained its dividend policy, targeting a stable or gradually rising dividend distribution in line with earnings growth and balance sheet strength. For fiscal 2025, Philips proposed a dividend of around EUR 0.85 per share, according to its shareholder information, compared with about EUR 0.80 per share for 2024. This modest increase signals confidence in the earnings trajectory while keeping the payout ratio at a manageable level.

Philips Sonicare as a flagship product

Philips Sonicare, the company’s flagship line of electric toothbrushes and oral-care devices, illustrates the group’s blend of consumer branding and health technology. Sonicare products are positioned as premium solutions that use high-frequency brush movements and tailored cleaning modes to improve oral hygiene. Philips has emphasized in marketing and investor materials that Sonicare continues to gain traction in key markets, with unit volumes and revenue contributing meaningfully to Personal Health segment performance.

From an investor perspective, Sonicare is representative of how Philips leverages its health-tech expertise in consumer categories. Product innovation cycles, such as new brush-head technologies, smartphone-connected brushing apps, and subscription models for replacement heads, support cross-selling and recurring revenue. The success of Sonicare also reinforces the Philips brand across broader healthcare offerings, as consumers associate the name with both professional and home-care devices.

Philips stock price and trading context

Philips stock is listed on Euronext Amsterdam under the symbol PHIA and also trades in the United States via NYSE-listed American Depositary Receipts (ADRs) under the symbol PHG. As of 16 July 2026, Philips shares on Euronext Amsterdam closed at EUR 22.30, with the ADRs on the NYSE corresponding to this level adjusted for ADR ratios. The current share price stands roughly midway between the 52-week low of around EUR 17.50 and the 52-week high near EUR 24.80, indicating that the market prices in both the progress on earnings recovery and the remaining recall-related uncertainties.

The market capitalization of about EUR 23 billion as of 16 July 2026 reflects a valuation multiple that is in line with, or slightly below, peers in the European medtech and health-tech space. When comparing Philips’ approximate price-to-earnings ratio based on 2025 earnings with those of companies focused purely on medtech, investors may view the stock’s discount as compensation for legal risks and the mixed portfolio. Volume in Philips shares tends to be concentrated on Euronext Amsterdam, with daily trading volumes reaching several million shares, providing ample liquidity for retail and institutional investors.

Philips stock key facts

• Company: Koninklijke Philips N.V.
• ISIN: NL0000009538
• Ticker: EURONEXT: PHIA
• Trading venue: Euronext Amsterdam
• Price (as of 16 July 2026, 17:30 CET): 22.30 EUR
• Market capitalization: 23,000,000,000 EUR (as of 16 July 2026)
• Sector / Industry: Health Technology / Medical Equipment and Services
• Index membership: AEX
• Next earnings date: 29 July 2026